FI61897C - Foerfarande foer framstaellning av nya terapeutiskt anvaendbara n-(1-(acyloximetyl)-4-(omega-nitroguanidino)-butyl)-dihydrolysergamider samt syraadditionssalter daerav - Google Patents
Foerfarande foer framstaellning av nya terapeutiskt anvaendbara n-(1-(acyloximetyl)-4-(omega-nitroguanidino)-butyl)-dihydrolysergamider samt syraadditionssalter daerav Download PDFInfo
- Publication number
- FI61897C FI61897C FI751537A FI751537A FI61897C FI 61897 C FI61897 C FI 61897C FI 751537 A FI751537 A FI 751537A FI 751537 A FI751537 A FI 751537A FI 61897 C FI61897 C FI 61897C
- Authority
- FI
- Finland
- Prior art keywords
- butyl
- therapeutic
- nitroguanidino
- acid
- dihydrolysergamider
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title description 4
- 101100148710 Clarkia breweri SAMT gene Proteins 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- -1 carboxylic acid halide Chemical class 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 125000005042 acyloxymethyl group Chemical group 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003420 antiserotonin agent Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000000794 anti-serotonin Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 206010027599 migraine Diseases 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 3
- UCVODTZQZHMTPN-UHFFFAOYSA-N heptanoyl chloride Chemical compound CCCCCCC(Cl)=O UCVODTZQZHMTPN-UHFFFAOYSA-N 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- YRUHAXVWQDPYQR-YFKPBYRVSA-N 2-[(4s)-5-hydroxy-4-nitramidopentyl]guanidine Chemical compound NC(N)=NCCC[C@@H](CO)N[N+]([O-])=O YRUHAXVWQDPYQR-YFKPBYRVSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000003176 neuroleptic agent Substances 0.000 description 2
- REEZZSHJLXOIHL-UHFFFAOYSA-N octanoyl chloride Chemical compound CCCCCCCC(Cl)=O REEZZSHJLXOIHL-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- WFZKRNIMSVDNBU-UHFFFAOYSA-N Creatinine sulfate mixture with serotonin Chemical compound [O-]S([O-])(=O)=O.C[NH+]1CC(=O)N=C1N.C1=C(O)C=C2C(CC[NH3+])=CNC2=C1 WFZKRNIMSVDNBU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ZAGRKAFMISFKIO-UHFFFAOYSA-N Isolysergic acid Natural products C1=CC(C2=CC(CN(C2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-UHFFFAOYSA-N 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000001954 decanoic acid esters Chemical class 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003509 long acting drug Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- ZAGRKAFMISFKIO-QMTHXVAHSA-N lysergic acid Chemical compound C1=CC(C2=C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-QMTHXVAHSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/02—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hydrocarbon or substituted hydrocarbon radicals, attached in position 8
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUGO1272A HU169073B (en, 2012) | 1974-05-28 | 1974-05-28 | |
| HUGO001272 | 1974-05-28 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI751537A7 FI751537A7 (en, 2012) | 1975-11-29 |
| FI61897B FI61897B (fi) | 1982-06-30 |
| FI61897C true FI61897C (fi) | 1982-10-11 |
Family
ID=10996767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI751537A FI61897C (fi) | 1974-05-28 | 1975-05-27 | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara n-(1-(acyloximetyl)-4-(omega-nitroguanidino)-butyl)-dihydrolysergamider samt syraadditionssalter daerav |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US4005089A (en, 2012) |
| JP (1) | JPS5218718B2 (en, 2012) |
| AT (1) | AT346501B (en, 2012) |
| BE (1) | BE829518A (en, 2012) |
| BG (1) | BG27374A3 (en, 2012) |
| CA (1) | CA1051878A (en, 2012) |
| CS (1) | CS194227B2 (en, 2012) |
| DD (1) | DD121639A5 (en, 2012) |
| DE (1) | DE2523743A1 (en, 2012) |
| DK (1) | DK143801C (en, 2012) |
| ES (1) | ES437994A1 (en, 2012) |
| FI (1) | FI61897C (en, 2012) |
| FR (1) | FR2272671B1 (en, 2012) |
| GB (1) | GB1474337A (en, 2012) |
| HU (1) | HU169073B (en, 2012) |
| IL (1) | IL47361A (en, 2012) |
| NL (1) | NL7506276A (en, 2012) |
| PL (1) | PL98944B1 (en, 2012) |
| SE (1) | SE419548B (en, 2012) |
| SU (1) | SU625612A3 (en, 2012) |
| YU (1) | YU135575A (en, 2012) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4064249A (en) * | 1974-05-28 | 1977-12-20 | Richter Gedeon Vegyeszeti Gyar Rt. | Compounds with ergoline skeleton |
| HU172649B (hu) * | 1975-04-24 | 1978-11-28 | Gyogyszerkutato Intezet | Sposob poluchenija novykh biologicheski aktivnykh lizergamidov |
| HU172479B (hu) * | 1976-03-09 | 1978-09-28 | Gyogyszerkutato Intezet | Sposob poluchenija novykh soedinenij s ehrgolenovymi i |
| JPS577172Y2 (en, 2012) * | 1977-03-17 | 1982-02-10 | ||
| JPS582957U (ja) * | 1981-06-30 | 1983-01-10 | 松下電子工業株式会社 | 高圧ナトリウムランプ |
| IT1171432B (it) * | 1981-08-03 | 1987-06-10 | Fidia Farmaceutici | Amidi organiche derivate da lipidi azotati utilizzabili come farmaci |
| US4675322A (en) * | 1984-12-10 | 1987-06-23 | Eli Lilly And Company | 1-Substituted-6-n-propyl-8β-methylthio-methylergolines |
| DD238051A1 (de) * | 1985-06-10 | 1986-08-06 | Dresden Arzneimittel | Verfahren zur herstellung neuer lysergsaeureamide |
| WO2011079313A1 (en) * | 2009-12-23 | 2011-06-30 | Map Pharmaceuticals, Inc. | Novel ergoline analogs |
| US8604035B2 (en) | 2011-06-23 | 2013-12-10 | Map Pharmaceuticals, Inc. | Fluoroergoline analogs |
| WO2013095707A1 (en) | 2011-12-19 | 2013-06-27 | Map Pharmaceuticals, Inc. | Novel iso-ergoline derivatives |
| EP2793583A4 (en) | 2011-12-21 | 2015-08-12 | Map Pharmaceuticals Inc | NOVEL NEUROMODULATORY CONNECTIONS |
| US9012640B2 (en) | 2012-06-22 | 2015-04-21 | Map Pharmaceuticals, Inc. | Cabergoline derivatives |
| MX2017009405A (es) * | 2015-01-20 | 2018-01-18 | Xoc Pharmaceuticals Inc | Compuestos de tipo ergolina y usos de estos. |
| EP3630758A1 (en) | 2017-06-01 | 2020-04-08 | Xoc Pharmaceuticals, Inc | Ergoline derivatives for use in medicine |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2533699A (en) * | 1950-12-12 | Amines containing the king system | ||
| US2673850A (en) * | 1951-07-28 | 1954-03-30 | Sandoz Ag | Piperazides of the lysergic acid series |
| US2946796A (en) * | 1958-10-15 | 1960-07-26 | Grace W R & Co | Salts of ergot alkaloids |
| CH475252A (de) * | 1966-02-08 | 1969-07-15 | Sandoz Ag | Verfahren zur Herstellung neuer Lysergsäure-Derivate |
| SE396753B (sv) * | 1970-05-18 | 1977-10-03 | Richter Gedeon Vegyeszet | Analogiforfarande for framstellning av en forening tillhorande dihydrolysergsyraserien |
| US3901893A (en) * | 1970-05-18 | 1975-08-26 | Richter Gedeon Vegyeszet | New dihydro-lysergic acid derivative |
| IL41409A (en) * | 1972-02-04 | 1977-04-29 | Richter Gedeon Vegyeszet | Lysergic acid amides and process for their preparation |
-
1974
- 1974-05-28 HU HUGO1272A patent/HU169073B/hu unknown
-
1975
- 1975-05-21 AT AT386375A patent/AT346501B/de not_active IP Right Cessation
- 1975-05-22 US US05/579,979 patent/US4005089A/en not_active Expired - Lifetime
- 1975-05-23 GB GB2283775A patent/GB1474337A/en not_active Expired
- 1975-05-25 YU YU01355/75A patent/YU135575A/xx unknown
- 1975-05-26 DD DD186250A patent/DD121639A5/xx unknown
- 1975-05-26 IL IL47361A patent/IL47361A/xx unknown
- 1975-05-26 SE SE7505974A patent/SE419548B/xx unknown
- 1975-05-26 BG BG030088A patent/BG27374A3/xx unknown
- 1975-05-27 FR FR7516377A patent/FR2272671B1/fr not_active Expired
- 1975-05-27 BE BE156729A patent/BE829518A/xx not_active IP Right Cessation
- 1975-05-27 FI FI751537A patent/FI61897C/fi not_active IP Right Cessation
- 1975-05-27 SU SU752144199A patent/SU625612A3/ru active
- 1975-05-27 CA CA227,849A patent/CA1051878A/en not_active Expired
- 1975-05-27 DK DK235175A patent/DK143801C/da not_active IP Right Cessation
- 1975-05-27 PL PL1975180710A patent/PL98944B1/pl unknown
- 1975-05-28 NL NL7506276A patent/NL7506276A/xx not_active Application Discontinuation
- 1975-05-28 ES ES437994A patent/ES437994A1/es not_active Expired
- 1975-05-28 DE DE19752523743 patent/DE2523743A1/de not_active Withdrawn
- 1975-05-28 JP JP50063984A patent/JPS5218718B2/ja not_active Expired
- 1975-05-28 CS CS753741A patent/CS194227B2/cs unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK143801C (da) | 1982-03-22 |
| AU8142575A (en) | 1976-11-25 |
| IL47361A0 (en) | 1975-07-28 |
| BE829518A (fr) | 1975-09-15 |
| JPS5218718B2 (en, 2012) | 1977-05-24 |
| HU169073B (en, 2012) | 1976-09-28 |
| DD121639A5 (en, 2012) | 1976-08-12 |
| FR2272671A1 (en, 2012) | 1975-12-26 |
| DK143801B (da) | 1981-10-12 |
| US4005089A (en) | 1977-01-25 |
| FI61897B (fi) | 1982-06-30 |
| FR2272671B1 (en, 2012) | 1978-10-06 |
| SE419548B (sv) | 1981-08-10 |
| BG27374A3 (bg) | 1979-10-12 |
| ATA386375A (de) | 1978-03-15 |
| FI751537A7 (en, 2012) | 1975-11-29 |
| SE7505974L (sv) | 1975-12-01 |
| YU135575A (en) | 1982-06-30 |
| PL98944B1 (pl) | 1978-05-31 |
| GB1474337A (en) | 1977-05-25 |
| CA1051878A (en) | 1979-04-03 |
| NL7506276A (nl) | 1975-12-02 |
| ES437994A1 (es) | 1977-01-16 |
| JPS516998A (en, 2012) | 1976-01-20 |
| DE2523743A1 (de) | 1975-12-18 |
| CS194227B2 (en) | 1979-11-30 |
| SU625612A3 (ru) | 1978-09-25 |
| AT346501B (de) | 1978-11-10 |
| DK235175A (da) | 1975-11-29 |
| IL47361A (en) | 1979-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI61897C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara n-(1-(acyloximetyl)-4-(omega-nitroguanidino)-butyl)-dihydrolysergamider samt syraadditionssalter daerav | |
| JP5596680B2 (ja) | 経口抗がん製剤 | |
| CN111295372B (zh) | 硝羟喹啉前药及其用途 | |
| JP7019000B2 (ja) | ２環性複素環化合物 | |
| FR2557110A1 (fr) | Nouveaux derives d'amines cycliques, leur preparation et leur utilisation comme medicaments | |
| KR20080091829A (ko) | 유방암, 대장암, 췌장암, 난소암 및 폐암 치료용 7―에틸―10―히드록시캄포테신의 다분지형 고분자 접합체 | |
| JP2009504625A (ja) | ジヒドロキシアントラキノンおよびそれらの使用 | |
| DE69521595T2 (de) | Optisch-aktives Benzothiepin-Derivate, ihre Herstellung und Verwendung | |
| AU1641592A (en) | Crystalline tiagabine hydrochloride monohydrate, its preparation and use | |
| EP0328111B1 (en) | Cancer cell metastasis inhibitors | |
| EP3998262A1 (en) | Nrf2-activating compound | |
| FR2775288A1 (fr) | Derives de streptogramines, leur preparation et les compositons qui les contiennent | |
| JP7503063B2 (ja) | 神経変性疾患の治療のための２－フッ素化胆汁酸 | |
| EP0072755B1 (fr) | Nouveaux derivés de la cephalosporine, leur préparation et les médicaments qui les contiennent | |
| US6066667A (en) | Substituted furanones, compositions and antiarthritic use | |
| EP4273145A1 (en) | Nrf2-activating compound | |
| CS199609B2 (en) | Method of producing 6-methyl-8-isocyanmethyl ergoline | |
| US4064249A (en) | Compounds with ergoline skeleton | |
| JPWO2003045953A1 (ja) | タキサン誘導体結晶およびその製造方法 | |
| EP0321090A2 (en) | Isoxazolidine-3,5-diones in the treatment of hyperlipidemia | |
| CN115043879A (zh) | 双氢青蒿素衍生物及其制备方法 | |
| CA2380305C (fr) | Derives de streptogramines, leur preparation et les compositions qui les contiennent | |
| CH641190A5 (fr) | Derives de la daunorubicine, leur preparation et les compositions pharmaceutiques qui les contiennent. | |
| JPH09508917A (ja) | フェニルピロール誘導体およびそのドーパミンｄ▲下３▼アンタゴニストとしての使用 | |
| AP639A (en) | Polymorphs of the pro drug 6-n-(L-Ala-L-Ala)-trovafloxacin. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: RICHTER GEDEON VEGYéSZETI GYAR R.T. |